Intervention/Treatment: The trial tests Itepekimab, administered subcutaneously in high and low doses, alongside Mometasone furoate nasal spray. The purpose is to improve symptoms in patients with ...

The approval in adolescent patients was based on evidence from the phase 3 SINUS-24 and SINUS-52 trials (ClinicalTrials.gov Identifier: NCT02912468 and NCT02898454, respectively), which compared ...

Dupixent surpassed Xolair in treating CRSwNP and asthma, improving symptoms and quality of life significantly. Quiver AI Summary New findings from the EVEREST Phase 4 trial presented at the 2025 ...

De Corso E, Baroni S, Onori ME, et al. Calprotectin in nasal secretion: a new biomarker of non-type 2 inflammation in CRSwNP. Acta Otorhinolaryngal Ital. Published online June 30, 2022. doi:10. ...

Patients also used mometasone furoate nasal spray. “Dupilumab outperformed omalizumab on all endpoints in both CRSwNP and asthma, while showing generally similar safety profiles,” De Corso said.

CRSwNP is a chronic disease of the upper airway, driven in part by type 2 inflammation, that obstructs the sinuses and nasal passages.

Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial.

Comprehensive research reveals significant insights into the burgeoning market for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), providing in-depth analysis that predicts a striking growth ...

Most people with a condition known as chronic rhinosinusitis with nasal polyps (CRSwNP) are able to control their symptoms by using medicines that are sprayed into the nose or taken by mouth. But ...

Most people with CRSwNP will be able to control their symptoms by using a type of medicine called a corticosteroid. This medicine can be sprayed directly into the nose (intranasal).

As for the ability of tissue SERPINB10 to be a predictive indicator of postop CRSwNP recurrence, although a link was seen between CRSwNP recurrence and tissue eosinophil percentage (odds ratio [OR ...